Have your own idea? Try our Stock Screener
Hong Kong (HSI) Healthcare Sector Analysis
UpdatedOct 10, 2025
DataAggregated Company Financials
Companies211
- 7D-4.1%
- 3M25.6%
- 1Y70.0%
- YTD87.0%
Over the last 7 days, the Healthcare industry has dropped 4.1%, and Sichuan Kelun-Biotech Biopharmaceutical contributed the most with a 9.2% decline. On the other hand 160 Health International is actually up 31%. In the past year, the industry has gained 70%. As for the next few years, earnings are expected to grow by 33% per annum.
Sector Valuation and Performance
Has the Hong Kong Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 10 Oct 2025 | HK$2.7t | HK$1.4t | HK$34.8b | 19.7x | 78.4x | 2x |
| Sun, 07 Sep 2025 | HK$2.8t | HK$1.5t | HK$37.4b | 18.6x | 75.5x | 1.9x |
| Tue, 05 Aug 2025 | HK$2.4t | HK$1.5t | HK$35.5b | 16.8x | 69x | 1.7x |
| Thu, 03 Jul 2025 | HK$2.0t | HK$1.5t | HK$35.7b | 14.8x | 57.4x | 1.4x |
| Sat, 31 May 2025 | HK$1.9t | HK$1.4t | HK$33.3b | 14.6x | 55.8x | 1.3x |
| Mon, 28 Apr 2025 | HK$1.7t | HK$1.4t | HK$32.4b | 14.1x | 51.9x | 1.2x |
| Wed, 26 Mar 2025 | HK$1.5t | HK$1.4t | HK$30.0b | 12.3x | 51x | 1.1x |
| Fri, 21 Feb 2025 | HK$1.5t | HK$1.4t | HK$29.1b | 12.6x | 50.5x | 1x |
| Sun, 19 Jan 2025 | HK$1.3t | HK$1.4t | HK$28.8b | 11.4x | 43.6x | 0.9x |
| Tue, 17 Dec 2024 | HK$1.4t | HK$1.4t | HK$29.2b | 11.9x | 46.3x | 1x |
| Thu, 14 Nov 2024 | HK$1.4t | HK$1.4t | HK$29.6b | 12.4x | 45.7x | 0.9x |
| Sat, 12 Oct 2024 | HK$1.5t | HK$1.5t | HK$30.5b | 13x | 48.7x | 1x |
| Mon, 09 Sep 2024 | HK$1.3t | HK$1.5t | HK$30.1b | 11.4x | 41.8x | 0.9x |
| Wed, 07 Aug 2024 | HK$1.2t | HK$1.4t | HK$27.9b | 10.3x | 43.9x | 0.9x |
| Fri, 05 Jul 2024 | HK$1.2t | HK$1.4t | HK$28.6b | 10.4x | 42.6x | 0.9x |
| Sun, 02 Jun 2024 | HK$1.3t | HK$1.4t | HK$28.7b | 12x | 45.2x | 0.9x |
| Tue, 30 Apr 2024 | HK$1.4t | HK$1.4t | HK$28.8b | 11.6x | 47.3x | 1x |
| Thu, 28 Mar 2024 | HK$1.3t | HK$1.4t | HK$28.6b | 11.8x | 46x | 0.9x |
| Sat, 24 Feb 2024 | HK$1.3t | HK$1.4t | HK$27.1b | 11.6x | 49.7x | 0.9x |
| Mon, 22 Jan 2024 | HK$1.4t | HK$1.4t | HK$26.0b | 11.4x | 52.6x | 1x |
| Wed, 20 Dec 2023 | HK$1.5t | HK$1.4t | HK$26.4b | 12.9x | 57.6x | 1.1x |
| Fri, 17 Nov 2023 | HK$1.7t | HK$1.4t | HK$25.2b | 12.8x | 66.6x | 1.2x |
| Sun, 15 Oct 2023 | HK$1.6t | HK$1.4t | HK$24.6b | 12.3x | 65.8x | 1.2x |
| Tue, 12 Sep 2023 | HK$1.6t | HK$1.4t | HK$25.2b | 12.7x | 63.2x | 1.1x |
| Thu, 10 Aug 2023 | HK$1.6t | HK$1.3t | HK$14.1b | 13.9x | 114.9x | 1.2x |
| Sat, 08 Jul 2023 | HK$1.7t | HK$1.4t | HK$2.5b | 13x | 669.2x | 1.2x |
| Mon, 05 Jun 2023 | HK$1.7t | HK$1.3t | HK$3.2b | 14x | 542.3x | 1.3x |
| Wed, 03 May 2023 | HK$1.9t | HK$1.4t | HK$4.4b | 16.9x | 436.2x | 1.4x |
| Fri, 31 Mar 2023 | HK$1.8t | HK$1.4t | HK$12.1b | 16.7x | 152.2x | 1.4x |
| Sun, 26 Feb 2023 | HK$1.9t | HK$1.3t | HK$2.0b | 16.1x | 948.2x | 1.4x |
| Tue, 24 Jan 2023 | HK$2.1t | HK$1.4t | HK$2.2b | 15.8x | 936.5x | 1.5x |
| Thu, 22 Dec 2022 | HK$1.8t | HK$1.3t | HK$2.1b | 14.1x | 840.4x | 1.4x |
| Sat, 19 Nov 2022 | HK$1.8t | HK$1.3t | HK$1.0b | 12.9x | 1734.1x | 1.4x |
| Mon, 17 Oct 2022 | HK$1.5t | HK$1.3t | HK$2.6b | 12.7x | 595.5x | 1.2x |
Price to Earnings Ratio
595.5x
Current Industry PE
- Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 78.4x which is lower than its 3-year average PE of 220x.
- The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 2.0x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have grown 138% per year over the last three years.
- Revenues for these companies have grown 2.7% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare sector?
| HK Market | -0.35% | |
| Healthcare | -4.11% | |
| Medical Equipment | 0.93% | |
| Healthcare Services | -0.62% | |
| Healthtech | -0.84% | |
| Pharma | -2.75% | |
| Life Sciences | -5.74% | |
| Biotech | -6.21% | |
Industry PE
- Investors are most optimistic about the Medical Equipment industry which is trading above its 3-year average PE ratio.
- Analysts are expecting annual earnings growth of 50.4%, which is higher than its past year's earnings growth of 9.7% per year.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 73% over the next 5 years.
- This is better than its past earnings decline of 2.2% per year.
- In contrast, the Pharma industry is expected to see its earnings grow by 14% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2656 160 Health International | HK$38.96 | 9.1% +HK$1.1b | n/a | PS18.8x | |
| 6681 BrainAurora Medical Technology | HK$9.07 | 9.5% +HK$1.0b | n/a | PS61.7x | |
| 1302 LifeTech Scientific | HK$2.15 | 9.1% +HK$833.7m | 25.7% | PE126.8x | |
| 1099 Sinopharm Group | HK$18.88 | 1.1% +HK$624.1m | -9.4% | PE7.9x | |
| 3320 China Resources Pharmaceutical Group | HK$4.89 | 1.2% +HK$377.0m | -18.0% | PE10x |
